Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
NCT ID: NCT00199004
Last Updated: 2010-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
60 participants
INTERVENTIONAL
2004-04-30
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
NCT00199056
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
NCT00198991
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
NCT00199069
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00198978
Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
NCT00199095
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyclophosphamide
Dexamethasone / Prednisolone
Vincristine
Daunorubicin
Asparaginase
Methotrexate
Cytarabine
Mercaptopurine
G-CSF
Vindesine
VP16
Adriamycin
Thioguanine
VM26
Rituximab
CNS irradiation
Mediastinal irradiation (if residual TU)
Stem cell transplantation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Standard risk
* CD20 expression \>20%
* Ph/BCR-ABL negative
* Age 15-65 years (55-65 if biologically younger)
* Written informed consent
Exclusion Criteria
* Late relapse of childhood ALL
* Cytostatic pretreatment
* Pregnancy
* Severe psychiatric illness or other circumstances which may compromise cooperation of the patient or informed consent
* Known severe allergy to foreign proteins
15 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johann Wolfgang Goethe University Hospital
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dieter Hoelzer, MD,PhD
Role: STUDY_CHAIR
University Hospital, Medical Dept. II
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Frankfurt, Medical Dept. II
Frankfurt, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
German Leukemia Trial Registry
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GMALL03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.